Text Size: a  |   a 

CVS Prescription Plan Drops "Big Name" MS Drugs from 2017 Formulary

August 17, 2016

The CVS Caremark covered insurance plan has dropped Avonex(interferon beta-1a), Plegridy (Peginterferon beta-1a) and Extavia (interferon beta-1b), three multiple sclerosis disease-modifying therapies, from their 2017 formulary.

If your prescription insurance is through CVS Caremark, and you want one of those drugs or one of the other 130 that were announced as off their formulary for next year, you can still get it, but you have to pay the full price. Your CVS Caremark insurance will no longer cover those costs unless your doctor is able to successfully appeal the formulary decisions.

“CVS Health is taking a stand against egregious drug price increases that unnecessarily add costs for clients and their members. On a quarterly basis, products with egregious cost inflation that have readily-available, clinically-appropriate and more cost-effective alternatives may be evaluated and potentially removed from the formulary. For example, among the hyperinflationary drugs that will be removed in 2017 is Alcortin A External Gel by Novum Pharmaceuticals which saw a price inflation of 2,856.8 percent in the last three years.”

“Our rigorous approach to formulary management will help generate a total savings of more than $9 billion for clients from 2012 through 2017.”